Pharming Group

PHAR

Market cap $1.25B

Pharming to participate in Oppenheimer Movers in Rare Disease Summit on Dec 11 in NYC. Chief Medical Officer Anurag Relan in fireside chat at 1:50 PM ET.

The mean of analysts' price targets for Pharming Group (PHAR) points to an 81.7% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Pharming Group N.V. Sponsored ADR (PHAR) shares have started gaining and might continue moving higher in the near term, as indicated by solid earnings estimate revisions.

The mean of analysts' price targets for Pharming Group (PHAR) points to a 100.9% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Pharming Group N.V. ( PHAR ) Q3 2025 Earnings Call November 6, 2025 7:30 AM EST Company Participants Fabrice Chouraqui - CEO & Executive Director Stephen Toor - Chief Commercial Officer & GM Americas Anurag Relan - Chief Medical Officer Kenneth Lynard - Chief Financial Officer Conference Call Participants Jeffrey Jones - Oppenheimer & Co. Inc., Research Division Lucy-Emma Codrington-Bartlett - Jefferies LLC, Research Division Natalia Webster - RBC Capital Markets, Research Division Simon Scholes - First Berlin Equity Research GmbH Presentation Operator Good day, and thank you for standing by.

Leiden, the  Netherlands, October 30, 2025: Pharming Group N.V. (“Pharming”) (Euronext Amsterdam: PHARM/Nasdaq: PHAR) announces that Pharming management will participate in the Jefferies Global Healthcare Conference in London, UK, on November 17-20, 2025.

Pharming to report third quarter 2025 financial results and provide a business update on November 6, 2025, and host conference call at 13:30 CET/07:30 ET.

Pharming announces 12 abstracts have been accepted for presentation at 2025 ACAAI Annual Scientific meeting being held in Orlando, Florida on November 6-10

Leiden, the Netherlands, October 6, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced the implementation of an organizational restructuring to accelerate the Company's growth.

If approved, leniolisib will be first and only treatment indicated for children with activated phosphoinositide 3-kinase delta (PI3Kδ) syndrome (APDS), a rare primary immunodeficiency Decision based on positive data from multinational Phase III study in children aged 4 to 11 years with APDS PDUFA target action date of January 31, 2026 Leiden, the Netherlands, October 1, 2025: Pharming Group N.V. (“Pharming” or “the Company”) (Euronext: PHARM; Nasdaq: PHAR) today announced that the U.S. Food and Drug Administration (FDA) has accepted its supplemental New Drug Application (sNDA) seeking approval for leniolisib, an oral, selective phosphoinositide 3-kinase delta (PI3Kδ) inhibitor, as a treatment for children aged 4 to 11 years with activated phosphoinositide 3-kinase delta syndrome (APDS), a rare primary immunodeficiency.